Abstracts
Submission of abstracts to European Drug Utilization Conference 2025 is now open! The deadline for submission is 31st of January, 2025. Submitters will be informed about the outcome of their submission by Thursday, 20th March, 2025.
Abstract submission guidelines
The European Drug Utilization Conference 2025 welcomes the submission of abstracts of original scientific work in the field of Drug Utilization Research (DUR).
The following categories of topics from DUR can be chosen in the abstract submission form:
- Accessibility of medicines
- availability and affordability of medications across different regions and healthcare systems, disparities in access between urban and rural areas, innovative models to improve access, etc.
- Adherence
- Measuring adherence
- Managing adherence
- Crisis preparedness
- Role of DUR in responding to public health crises, such as pandemics, natural disasters, conflicts or other emergencies.
- Cross-national comparisons
- Comparative studies on drug utilization across countries, identifying best practices, understanding the impact of different healthcare systems on drug use, and addressing disparities.
- Digitalization, Big Data and AI in DUR
- The use of technology to collect, analyze, and interpret large datasets in DUR.
- Drugs & environment
- The environmental impact of pharmaceuticals, from manufacturing to disposal, one-health, and initiatives to reduce environmental burden of pharmaceuticals.
- Health policy and DUR
- How pricing regulations, formulary management, reimbursement and other policies influence drug utilization.
- Interventions and implementation
- Strategies to improve drug utilization through interventions including, but not limited to, educational programs, clinical guidelines, electronic prescribing alerts etc., and assessing the effectiveness of these interventions in different settings.
- Methods in DUR
- New analytical techniques, study designs, and data sources.
- Patients perspectives
- Quantitative and qualitative studies focusing on patient reported outcomes.
- Polypharmacy
- Polypharmacy, deprescribing initiatives, medication reviews, and integrated care approaches.
- Quality of medicine use
- Studies focusing on that safe and effective medicine use, describing or using quality indicators, guideline development and implementation.
- Safety and DUR
- Pharmacovigilance, risk minimization strategies, and post-marketing surveillance.
- Specific populations
- Children, older people, pregnancy, sex and gender differences, socio-economic impact on drug utilization, etc.
- Specific therapeutic areas
- Cardiovascular, cancer, antibiotics, analgesics, psychotropics etc.
Abstracts should include 4 paragraphs: Background, Methods, Results, Conclusion.
The abstract body should be maximum 250 words (excluding title and author information). There is a word counter at the bottom right corner of the abstract body textbox. Tables, figures or complete references are not accepted in the abstracts. Please use the electronic abstract submission system.
In submitting an abstract you have to agree to the following terms and conditions:
- I confirm that each author/ presenter listed agrees with the content of the abstract submitted for the European Drug Utilization Conference 2025 and has given permission to be listed as an author/ presenter.
- Where required, I have obtained the necessary research ethics approval for the project described in the abstract submitted.
- I confirm that the work described in the abstract is original scientific material.
- I understand that, should my abstract be accepted for oral/short oral communication/poster presentation, the presenting author is required to registrate for the European Drug Utilization Conference 2025. My abstract will not be included in the final program and the program book until registration and full payment have been received.
- I hereby provide permission to the EuroDURG Conference Scientific Committee to publish my accepted abstract in the Abstract Book, on the European Drug Utilization Conference 2025 website.
- I acknowledge that my e-mail address and mail address will only be used by the congress organizers for contacting me within the framework of the conference. On the other hand, EuroDURG will use my e-mail address to send me further information about their activities (no more than a few times a year). My contact details will never be given to a third party.
- Information about possibility to give either a) oral presentation or b) short oral communication alongside digital poster.
During submission of abstracts authors will be asked to select from two options:
- a) oral presentation - 15 min. presentation on submitted research in one of the sessions of selected topic.
- b) digital poster and short oral communication (PSOC) – 5 min. short oral communication in the PSOC session presenting one slide (digital poster). Digital posters will be made available online through out entire conference. If accepted, authors will be asked to send their photo for “authors&digital posters map” which will be printed and placed in the conference venue. One slide – digital poster requirements will follow after abstract submission deadline.